Aligos Therapeutics, Inc. ALGS · Stock Open Aligos Therapeutics, Inc. in new tab
Aligos Therapeutics, Inc. Analysis (ALGS)
Is Aligos Therapeutics, Inc. a good investment? Aligos Therapeutics, Inc. (ALGS) is currently trading at 4.60 USD. Market analysts have a consensus price target of 56.29 USD. This suggests a potential upside from current levels.
Earnings Schedule: Aligos Therapeutics, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -3.99.
Investor FAQ
Does Aligos Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -9.78.
Company Profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 19, 2024 | 0.040000 |
Community Discussion